Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Sanofi-Aventis Deutschland v. Glenmark Pharmaceuticals, No. 12-1489 (Fed. Cir. Apr. 21, 2014)

Affirmed in Part
Infringement Invalidity (§ 102/§ 103) Damages
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 12-1489
Decided
April 21, 2014
Judge
Newman, J.
Document
Precedential Opinion
Length
19 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This patent infringement suit concerns the antihyper- tension drug having the brand name Tarka®. Tarka® is a combination of two active ingredients into a single dosage product: the angiotensin converting enzyme (ACE) inhibi- tor trandolapril, and the calcium channel blocker (also called “ calcium antagonist ”) verapamil hydrochloride. The combination drug is covered by United States Patent No. 5,721,244 (the ’244 patent) and is owne d by or excl u- sively licensed to Sanofi -Aventis Deutschland GmbH (a company of Germany), Aventis Pharma S.A.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error